-
Innovent Biologics Partners with ImmVirX to Launch Clinical Study Combining Tyvyt and IVX037
•
Innovent Biologics Inc. (HKG: 1801), based in China, has announced the signing of a clinical study and supply cooperation agreement with ImmVirX Pty Ltd. This strategic partnership will facilitate a clinical study that combines Innovent’s Tyvyt (sintilimab), a programmed death-1 (PD-1) inhibitor already approved in China for seven different indications,…
-
Biogen Appoints Ding Weibo as Head of Asia-Pacific Region, Succeeding Francis Wan
•
Biogen (NASDAQ: BIIB) has announced the appointment of Ding Weibo as the new head of its Asia-Pacific region, reporting directly to Fraser Hall, the head of Biogen’s Intercontinental Market. Ding succeeds Francis Wan in this pivotal role. Ding Weibo brings a wealth of experience from his tenure at several multinational…
-
Shenzhen Eureka Biotechnology Secures RMB 300 Million in Series B+ Funding for CGT Expansion
•
Shenzhen Eureka Biotechnology Co., Ltd., a specialist in cell and gene therapy (CGT) based in China, has successfully raised over RMB 300 million (approximately USD 41.7 million) in a Series B+ financing round. The funding was led by Yuexiu Capital, with notable participation from Fortune Capital, Guangdong Technology Financial Group,…
-
Mabwell Bioscience Receives FDA Green Light for B7-H3 Targeting ADC 7MW3711
•
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a clinical study for its antibody drug conjugate (ADC) 7MW3711, which targets B7-H3. The molecule is intended to be assessed…
-
BMS and Sichuan Biokin Commence Joint Development of EGFR/HER3-Targeted ADC
•
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese pharmaceutical company, has announced that a licensing and cooperation agreement with US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has officially come into effect as of February 8, 2024, following the expiration of the waiting period for the deal. The agreement…
-
Everest Medicines Terminates Agreement with Providence Therapeutics, Retains mRNA Rights
•
Everest Medicines (HKG: 1952), a biopharmaceutical company based in China, has announced the termination of a cooperation and licensing agreement with Providence Therapeutics (PTx), a Canadian RNA medicines company. Following the termination, Everest Medicines will independently continue the development of preventative and therapeutic mRNA products using the mRNA platform, holding…
-
Jacobio Pharma Gets CDE Green Light for Phase III Study Combining Gleevec Inhibitors in NSCLC
•
Jacobio Pharma (HKG: 1167), a China-based pharmaceutical company, has announced that it has received approval from the Center for Drug Evaluation (CDE) in China to initiate a regulatory Phase III clinical study. The study will assess the combination of its KRAS G12C inhibitor glecirasib with pipeline SHP2 inhibitor JAB-3312 for…
-
Neurophth Biotechnology Completes Enrollment and Dosing in US Clinical Study for ND4-LHON Gene Therapy
•
Neurophth Biotechnology Ltd, a leading gene therapy specialist based in China, has announced the completion of patient enrollment and dosing in a Phase I/II clinical study for its investigational drug NR082 (rAAV2-ND4; NFS-01) in the United States. The study targets ND4-mediated Leber’s hereditary optic neuropathy (ND4-LHON). The single-arm, multi-center Phase…
